From: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
Per-nodule | |||
---|---|---|---|
1 months | 0.33 | ||
Complete response | 42.4% (81/191) | 40.0% (14/35) | 0.79 |
Partial response | 19.9% (38/191) | 25.7% (9/35) | 0.44 |
Stable disease | 34.6% (66/191) | 25,7% (9/35) | 0.31 |
Progressive disease | 3.1% (6/191) | 8.6% (3/35) | 0.13 |
Objective response | 62.3% (119/191) | 65.7% (23/35) | 0.70 |
Disease control | 96.8% (185/191) | 91.4% (32/35) | 0.13 |
3–6 months | 0.14 | ||
Complete response | 45.6% (62/136) | 44.8% (13/29) | 0.94 |
Partial response | 11.8% (16/136) | 27.6% (8/29) | 0.03° |
Stable disease | 30.1% (41/136) | 20.7% (6/29) | 0.31 |
Progressive disease | 12.5% (17/136) | 6.9% (2/29) | 0.39 |
Objective response | 57.4% (78/136) | 72.4% (21/29) | 0.13 |
Disease control | 87.5% (119/136) | 93.1% (27/29) | 0.39 |
9–12 months | 0.03 | ||
Complete response | 50.6% (45/89) | 68.4% (13/19) | 0.24 |
Partial response | 3.4% (3/89) | 10.5% (2/19) | 0.18 |
Stable disease | 30.3% (27/89) | 0% (0/19) | 0.006 |
Progressive disease | 15.7% (14/89) | 21.1% (4/19) | 0.57 |
Objective response | 53.9% (48/89) | 78.9% (15/19) | 0.05 |
Disease control | 84.3% (75/89) | 78.9% (15/19) | 0.50 |